- Conditions
- Rett Syndrome
- Interventions
- TSHA-102
- Genetic
- Lead sponsor
- Taysha Gene Therapies, Inc.
- Industry
- Eligibility
- 6 Years to 21 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 8
- States / cities
- Duarte, California • La Jolla, California • Oakland, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1561–1584
of 3,785
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-hodgkin Lymphoma, Hodgkin Lymphoma
- Interventions
- DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B, DOC Group C, MAD CPR 1 and 2, Pv-R CYVE 1 and 2, Pv-R CYVE-MTX 1 and 2, MAD CP, Pv-Cytarabine/etoposide, AD CP, Bv-AVD-R 1 and 2: COHORT IIa, Bv-NVD-R, Cycle 1-2, Bv-NVD-R, Cycle 1-4 SER, Bv-AVD-R, Bv-NVD-R, Cycle 1-4 RER, Bv-NAVD-R, Cycle 1-2, Involved Site Radiation Therapy
- Drug · Radiation
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Gainsville, Florida • Vallhala, New York
- Conditions
- Bacterial Infections
- Interventions
- [18F]fluoropropyl-trimethoprim
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer, Alcohol Drinking
- Interventions
- Sobriety Digital Intervention
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Cystic Fibrosis
- Interventions
- IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more
- Conditions
- Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia, CML, Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Itacitinib
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes Mellitus
- Interventions
- HM11260C, Placebo, Victoza
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- California City, California
- Conditions
- Breast Cancer
- Interventions
- Everolimus, Fulvestrant
- Drug
- Lead sponsor
- Mara Chambers
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
- Interventions
- Durvalumab, Monalizumab
- Drug
- Lead sponsor
- John Sfakianos
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 5
- States / cities
- San Francisco, California • Tampa, Florida • New Brunswick, New Jersey + 1 more
- Conditions
- Acute Compartment Syndrome
- Interventions
- Near infrared spectroscopy (NIRS)
- Device
- Lead sponsor
- J&M Shuler
- Industry
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Vitamin d Deficiency, Secondary Hyperparathyroidism
- Interventions
- CTAP101, Placebo
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Greenville, South Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 16
- States / cities
- Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- Magrolimab, Rituximab, Gemcitabine, Oxaliplatin, Allopurinol
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Duarte, California • Stanford, California + 12 more
- Conditions
- Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma
- Interventions
- Cemiplimab, Computed Tomography, Biospecimen Collection, Quality-of-Life Assessment, Magnetic Resonance Imaging, Biopsy, Fianlimab
- Biological · Procedure · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 3
- States / cities
- Miami, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee
- Conditions
- Lower Urinary Tract Symptoms
- Interventions
- Observational, Observational Controls, Central Sensitization, Physical Activity and Sleep Tracker, Physical Activity and Sleep Tracker Controls, Organ-Based, Qualitative Assessment of Patients with Urinary Urgency
- Other
- Lead sponsor
- Arbor Research Collaborative for Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,030 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 3 more
- Conditions
- Advanced Lung Cancer
- Interventions
- BNT324, BNT327
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 13 more
- Conditions
- Perioperative/Postoperative Complications, Aerobic Capacity
- Interventions
- Shape II
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 371 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Gastrointestinal Tract Malignancies
- Interventions
- Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 12 more
- Conditions
- HIV Infections
- Interventions
- CPT31, Placebo
- Drug
- Lead sponsor
- Navigen, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Healthy Volunteers
- Interventions
- TS-142, TS-142 Placebo
- Drug
- Lead sponsor
- Taisho Pharmaceutical R&D Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- Felzartamab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 29
- States / cities
- Little Rock, Arkansas • Apple Valley, California • Carlsbad, California + 25 more
- Conditions
- Tobacco Use Disorder, Smoking Cessation
- Interventions
- Web-based curriculum on tobacco dependence treatment, Tobacco Counseling Role Play, Preceptor Training and Teaching Medical Students, Booster Session
- Behavioral
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Stanford, California • Washington D.C., District of Columbia + 10 more
- Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 13
- States / cities
- Clovis, California • Duarte, California • Chicago, Illinois + 10 more
- Conditions
- Melanoma (Skin)
- Interventions
- ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama